Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Xilio Therapeutics, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 35 | 36 | +1 |
| Shares | 23.8M | 22.1M | −1.74M (−7.3%) |
| Value | $16.2M | $18.6M | +$2.43M (+15.0%) |
New holders (4)
Institutions that held Xilio Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Two Sigma Securities, LLC | 32,130 | $27.1K | 0.00% |
| Two Sigma Advisers, LP | 29,689 | $25.0K | 0.00% |
| HRT Financial LP | 24,736 | $20.0K | 0.00% |
| Citigroup Inc | 258 | $217 | 0.00% |
Sold out (3)
Institutions that held Xilio Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Ghisallo Capital Management LLC | 1,333,000 | $906.3K |
| Avantax Planning Partners, Inc. | 142,338 | $96.8K |
| Tower Research Capital LLC (TRC) | 15,412 | $10.5K |